427 related articles for article (PubMed ID: 20693839)
21. [The interplay of immunotherapy and chemotherapy, a novel approach].
Hanoteau A; Henin C; Moser M
Med Sci (Paris); 2016 Apr; 32(4):353-61. PubMed ID: 27137692
[TBL] [Abstract][Full Text] [Related]
22. [Biotherapy of solid tumors].
Moiseenko VM
Vopr Onkol; 1998; 44(1):120-5. PubMed ID: 9578746
[No Abstract] [Full Text] [Related]
23. Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?
Holtick U; Klein-Gonzalez N; von Bergwelt-Baildon MS
Immunotherapy; 2011 Mar; 3(3):301-4. PubMed ID: 21395370
[No Abstract] [Full Text] [Related]
24. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.
Bracci L; Schiavoni G; Sistigu A; Belardelli F
Cell Death Differ; 2014 Jan; 21(1):15-25. PubMed ID: 23787994
[TBL] [Abstract][Full Text] [Related]
25. [Benefits of combining chemotherapy with immuno- oncology therapies or "Is it true that chemotherapy destroys the immune system?"].
Kocsis J
Magy Onkol; 2019 Sep; 63(3):202-207. PubMed ID: 31533140
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery.
Goldberg EP; Hadba AR; Almond BA; Marotta JS
J Pharm Pharmacol; 2002 Feb; 54(2):159-80. PubMed ID: 11848280
[TBL] [Abstract][Full Text] [Related]
27. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
Stevenson HC; Klein HG
Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
[No Abstract] [Full Text] [Related]
28. The inducers of immunogenic cell death for tumor immunotherapy.
Li X
Tumori; 2018; 104(1):1-8. PubMed ID: 28967094
[TBL] [Abstract][Full Text] [Related]
29. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
30. Adapting conventional cancer treatment for immunotherapy.
Qiao J; Liu Z; Fu YX
J Mol Med (Berl); 2016 May; 94(5):489-95. PubMed ID: 26910191
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.
Ding ZC; Zhou G
Clin Dev Immunol; 2012; 2012():890178. PubMed ID: 22400040
[TBL] [Abstract][Full Text] [Related]
32. The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.
Kerr WG; Chisholm JD
J Immunol; 2019 Jan; 202(1):11-19. PubMed ID: 30587569
[TBL] [Abstract][Full Text] [Related]
33. The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right.
Park DS; Robertson-Tessi M; Luddy KA; Maini PK; Bonsall MB; Gatenby RA; Anderson ARA
Cancer Res; 2019 Oct; 79(20):5302-5315. PubMed ID: 31387920
[TBL] [Abstract][Full Text] [Related]
34. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.
Shahabi V; Postow MA; Tuck D; Wolchok JD
Am J Clin Oncol; 2015 Feb; 38(1):90-7. PubMed ID: 25616204
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
36. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh L; Ladoire S; Coukos G; Ghiringhelli F
Ann Oncol; 2015 Sep; 26(9):1813-1823. PubMed ID: 25922066
[TBL] [Abstract][Full Text] [Related]
37. Combining cancer vaccines with chemotherapy.
Chong G; Morse MA
Expert Opin Pharmacother; 2005 Dec; 6(16):2813-20. PubMed ID: 16318432
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies for medical oncology: a few critical perspectives.
Belda-Iniesta C; Ibáñez de Cáceres I; de Castro J
Clin Transl Oncol; 2011 Feb; 13(2):84-7. PubMed ID: 21324795
[TBL] [Abstract][Full Text] [Related]
39. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
[TBL] [Abstract][Full Text] [Related]
40. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.
Ménard C; Martin F; Apetoh L; Bouyer F; Ghiringhelli F
Cancer Immunol Immunother; 2008 Nov; 57(11):1579-87. PubMed ID: 18369619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
